A clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens
Authors:
Open Access
- 7 May 2018
- journal article
- research article
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 6 (3) , 382-391
Abstract
Introduction: Omalizumab has been available for treatment of allergic asthma for more than a decade and thus, its efficacy in routine treatment was of interest to evaluate. Basophil allergen threshold sensitivity (CD‐sens) has been shown to correlate with the bronchial allergen threshold sensitivity and can be used to objectively measure omalizumab treatment efficacy. We aimed to evaluate the effect of omalizumab treatment of allergic asthma by CD‐sens, as an objective marker of the IgE‐mediated inflammation, and related to SPT, spirometry, FeNO, Asthma Control Questionnaire (ACQ), and Global Evaluation of Treatment Effectiveness (GETE).Methods: Thirty‐two patients were treated with omalizumab for 16 weeks. CD‐sens was used to define the response and related to clinical parameters. If CD‐sens was negative (p < 0.05) and further 3/15 patients became CD‐sens negative (CD‐sens at 32 weeks: 0.5). There was a significantly smaller IgE‐ab fraction (IgE‐ab/IgE) in the CD‐sens low versus the CD‐sens high Group (p < 0.0001). A significant decrease in ACQ was seen in both groups after 16 weeks treatment (p = 0.05 and 0.01, respectively). No significant changes could be detected for the other clinical parameters.Conclusion: By the use of the objective laboratory method CD‐sens, which effectively measure the direct effect of omalizumab, that is, the IgE‐mediated part of the allergic asthma, in combination with clinical parameters it might be possible to more effectively monitor and treat IgE‐mediated allergic asthma.Keywords
This publication has 30 references indexed in Scilit:
- Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life studyPostgraduate Medicine, 2017
- The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthmaInternational Journal of Clinical Pharmacy, 2014
- Successful management of severe cow’s milk allergy with omalizumab treatment and CD-sens monitoringAsia Pacific Allergy, 2014
- Basophil activation test discriminates between allergy and tolerance in peanut-sensitized childrenJournal of Allergy and Clinical Immunology, 2014
- The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthmaRespiratory Medicine, 2013
- Basophil allergen threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthmaClinical & Experimental Allergy, 2011
- The size of the disease relevant IgE antibody fraction in relation to ‘total‐IgE’ predicts the efficacy of anti‐IgE (Xolair®) treatmentAllergy, 2009
- Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label studyRespiratory Medicine, 2008
- Passive IgE‐sensitization by blood transfusionAllergy, 2005
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical & Experimental Allergy, 2004